Patents by Inventor Chenguang LIANG

Chenguang LIANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230288406
    Abstract: A transformative method to profile the glycome in individual cells by leveraging computational biology tools with lectin or similar profiling technologies. Robust and accurate reconstruction glycomes with high-resolution glycan structure information for biological samples, including at the single cell level. Tools such as single-clone analysis andjoint-clone analysis, which may be used to assist researchers in analyzing single cell glycoprofiled samples, which identify how glycosylation variation across cells impact the cellular phenotypes. Single cell glycoprofiling using lectins is practically implemented to provide high resolution of the glycan structure information. Glycan profiling techniques having a wide range of biological applications from embryonic development to cancer and infectious disease due to high throughput, low cost, and robust reliability.
    Type: Application
    Filed: August 2, 2021
    Publication date: September 14, 2023
    Inventors: Nathan Lewis, Wan-Tien Chiang, Chenguang Liang, James T. Sorrentino
  • Publication number: 20230099373
    Abstract: Glycosylated biopharmaceuticals are important in the global pharmaceutical market. Despite the importance of their glycan structures, our limited knowledge of the glycosylation machinery still hinders controllability of this critical quality attribute. To facilitate discovery of glycosyltransferase specificity and predict glycoengineering efforts, here we extend an approach to model biosynthetic pathways for all measured glycans, and the Markov chain modeling is used to learn glycosyltransferase isoform activities and predict glycosylation following glycosyltransferase knock-in/knockout. We apply our methodology to four different glycoengineered therapeutics (i.e., Rituximab, erythropoietin, Enbrel, and alpha-1 antitrypsin) produced in CHO cells, along with o-glycosylation and lipid profiles. Our models accurately predict N-linked glycosylation following glycoengineering and further quantified the impact of glycosyltransferase mutations on reactions catalyzed by other glycosyltransferases.
    Type: Application
    Filed: November 19, 2020
    Publication date: March 30, 2023
    Inventors: Nathan E. Lewis, Wan-Tien Chiang, Chenguang Liang
  • Publication number: 20170036189
    Abstract: Emulsions are dispersed systems wherein one phase is dispersed in another immiscible phase. Stabilized emulsions with small droplets are typically slow to phase separate and require elevated demulsifier dosage to counteract the stabilizing effect of surfactants, fine bi-wetting particles, or both; and promote droplet coalescence. The compositions and processes of the present invention are useful in removing stabilized water droplets from an emulsion with non-aqueous continuous phase. The composite absorbent particle is ideally suited to removed emulsified water through absorption of emulsified water.
    Type: Application
    Filed: June 17, 2016
    Publication date: February 9, 2017
    Inventor: Chenguang LIANG